|
Table 2: Clinical scenarios in which polygenic risk score may modify decision-making in primary prevention. |
||
|
Recommendation |
Class |
Level |
|
Use of PRS in young adults with family history of premature coronary artery disease |
IIa |
B |
|
Use of PRS in individuals with intermediate risk and therapeutic uncertainty |
IIa |
B |
|
Use of PRS to support intensification of lipid-lowering strategies in primary prevention |
IIb |
B |
|
PRS should not be used as a standalone decision-making tool |
III |
C |
|
Validation of PRS in the Mexican population prior to widespread implementation |
I |
C |
|
PRS = Polygenic Risk Score. Classification of recommendations and levels of evidence adapted from the European Society of Cardiology (ESC) Guidelines.6,7,16 |
||